Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor

Life Health > Health Insurance

Gen Re posts China dread disease numbers

X
Your article was successfully shared with the contacts you provided.

Gen Re actuaries have published an analysis aimed at insurers that are starting to think about selling dread disease insurance in China.

See also: Critical illness insurance premium revenue climbs 15%

Wolfgang Droste, a consultant, and Jianbo Xiang, a senior actuary, have given readers a glimpse of recent trends in incidence rates for several representative conditions: female breast cancer, female thyroid cancer, male stroke, female stroke and male heart attack.

The authors show, for example, that women in China seem to have a high, and rapidly rising, rate of female thyroid cancer with at least some of the increase likely due to the popularity of ultrasound screening.

However the reported incidence of breast cancer is low in China, in part because the government does not subsidize regular screening for breast cancer, the authors say.

The authors also give maps showing the incidence of all dread diseases in different Chinese provinces. For both men and women, the northeastern provinces tend to have above-average incidence rates, and the western regions tend to have low incidence rates.

Shanghai, the largest and most populous city in China and the world, has moderate incidence rates for women and low incidence rates for men.

See also:

Health broker: Non-PPACA market is jumping

Critical Illness: Insurers Report $227 Million in U.S. Sales

        

Are you following us on Facebook?


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.